Oxidative Stress and Neuroprotection
This book deals with basic and clinical aspects of monoamine oxidase (MAO) subtypes A and B highlighting its importance in neurological and psychiatric diseases. Consequently the therapeutic actions of MAO-A and -B inhibitors in Parkinson’s disease (PK) and depression are the focus of several chapte...
| Συγγραφή απο Οργανισμό/Αρχή: | |
|---|---|
| Άλλοι συγγραφείς: | , |
| Μορφή: | Ηλεκτρονική πηγή Ηλ. βιβλίο |
| Γλώσσα: | English |
| Έκδοση: |
Vienna :
Springer Vienna,
2006.
|
| Σειρά: | Journal of Neural Transmission. Supplementa ;
71 |
| Θέματα: | |
| Διαθέσιμο Online: | Full Text via HEAL-Link |
Πίνακας περιεχομένων:
- Levodopa in the treatment of Parkinson’s disease
- Changing dopamine agonist treatment in Parkinson’s disease: experiences with switching to pramipexole
- The DONPAD-study — Treatment of dementia in patients with Parkinson’s disease with donepezil
- PD-related psychosis: pathophysiology with therapeutical strategies
- Antioxidant capacity in postmortem brain tissues of Parkinson’s and Alzheimer’s diseases
- Apoptosis inhibition in T cells triggers the expression of proinflammatory cytokines — implications for the CNS
- Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson’s disease: possible implications of glial cells
- Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection
- The relationship of early studies of monoamine oxidase to present concepts
- Isatin, an endogenous MAO inhibitor, and a rat model of Parkinson’s disease induced by the Japanese encephalitis virus
- Isatin interaction with glyceraldehyde-3-phosphate dehydrogenase, a putative target of neuroprotective drugs: partial agonism with deprenyl
- Inhibition of amine oxidases by the histamine-1 receptor antagonist hydroxyzine
- Neuroprotection for Parkinson’s disease
- Marker for a preclinical diagnosis of Parkinson’s disease as a basis for neuroprotection
- Assessing neuroprotection in Parkinson’s disease: from the animal models to molecular neuroimaging in vivo
- Deprenyl: from chemical synthesis to neuroprotection
- The use of rasagiline in Parkinson’s disease
- Novel neuroprotective neurotrophic NAP analogs targeting metal toxicity and oxidative stress: potential candidates for the control of neurodegenerative diseases
- Acute and chronic effects of developmental iron deficiency on mRNA expression patterns in the brain
- Long lasting effects of infancy iron deficiency — Preliminary results
- Altered regulation of iron transport and storage in Parkinson’s disease
- Iron dyshomeostasis in Parkinson’s disease
- Cerebral oligemia and iron influence in cerebral structures — element of Morbus Parkinson Models?
- Impact of selenium, iron, copper and zinc in on/off Parkinson’s patients on L-dopa therapy
- Metal specificity of an iron-responsive element in Alzheimer’s APP mRNA 5?untranslated region, tolerance of SH-SY5Y and H4 neural cells to desferrioxamine, clioquinol, VK-28, and a piperazine chelator
- Green tea catechins as brain-permeable, non toxic iron chelators to “iron out iron” from the brain.
